Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 1/2012

01.01.2012 | 2011 SSAT Plenary Presentation

Innate Immune Environment in Ileal Pouch Mucosa: α5 Defensin Up-regulation as Predictor of Chronic/Relapsing Pouchitis

verfasst von: Marco Scarpa, Alessia Grillo, Melania Scarpa, Paola Brun, Carlo Castoro, Anna Pozza, Donatella Cavallo, Diego Faggian, Cesare Ruffolo, Renata D’Incà, Romeo Bardini, Ignazio Castagliuolo, Imerio Angriman

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Defensins are small cationic peptides with antibacterial activity expressed in Paneth cells (α-defensins) or generally in intestinal epithelial cells (β-defensins) that have a profound effect on gut microbiota. Chronic pouchitis, which occurs in 5% of patients after restorative proctocolectomy and can cause pouch failure, is associated to a significant increase of Clostridiaceae spp. The aim of this study was to gain further insight in the pathogenesis of pouch dysbiosis by exploring defensin expression. Thirty-two consecutive patients coming for follow-up endoscopy were recruited. On pouch biopsies, we cultured bacteria adherent to the mucosa and determined α- and β-defensins and toll-like receptor-4 and −2 mRNA by quantitative real-time RT-PCR. Serum and mucosal levels of IL-1β, IL-6 and TNF-α were measured with immunometric assays. Faecal lactoferrin was analysed by quantitative ELISA. After a median follow-up of 23 (IQR 20–24) months, the patients were contacted for a reassessment of current and past disease activity. During the follow-up, chronic/relapsing pouchitis was diagnosed in six patients. The mucosal level of α-5 and α-6 defensins correlated with chronic/relapsing pouchitis onset (τ = 0.30, p = 0.034 and τ = 0.28, p = 0.053, respectively). High levels of α-5 defensin resulted to be predictive of chronic/relapsing pouchitis [AUC = 74% (95% CI = 53–89%), p = 0.052]. Patients with high levels of α-5 and α-6 defensins had earlier pouchitis relapses (p = 0.009 and p = 0.034, respectively). High levels of α-5 defensin were associated to a significant risk of chronic/relapsing pouchitis [OR = 10.6 (95% CI = 1.2–97.6), p = 0.027]. At multivariate analysis, the mucosal levels of α-5 defensin and the number of CFU of mucosa-associated Clostridiaceae spp resulted to be independent predictors of chronic/relapsing pouchitis [β = 0.46 (0.18), p = 0.024 and β = 0.44 (0.18), p = 0.027, respectively]. In conclusion, chronic/relapsing pouchitis is associated to increased expression of mucosal HD-5 and to increased antimicrobial activity against Escherichia coli. In patients with chronic/relapsing pouchitis, HD-5 and TLR-4 over-expression is likely to create a hostile environment against Enterobacteriaceae, thus favouring Clostridiaceae spp by decreasing competing bacteria families.
Literatur
1.
Zurück zum Zitat Onaitis MW, Mantyh C. Ileal pouch–anal anastomosis for ulcerative colitis and familial adenomatous polyposis: historical development and current status. Ann Surg 2003 238(6 Suppl):S42–S48.PubMed Onaitis MW, Mantyh C. Ileal pouch–anal anastomosis for ulcerative colitis and familial adenomatous polyposis: historical development and current status. Ann Surg 2003 238(6 Suppl):S42–S48.PubMed
2.
Zurück zum Zitat Fazio VW, Ziv Y, Church JM, Oakley JR, Lavery IC, Milsom JW, Schroeder TK. Ileal pouch–anal anastomoses complications and function in 1005 patients. Ann Surg 1995;222:120–7.PubMedCrossRef Fazio VW, Ziv Y, Church JM, Oakley JR, Lavery IC, Milsom JW, Schroeder TK. Ileal pouch–anal anastomoses complications and function in 1005 patients. Ann Surg 1995;222:120–7.PubMedCrossRef
3.
Zurück zum Zitat Sandborn WJ, Pardi DS. Clinical management of pouchitis. Gastroenterology 2004;127:1809–14.PubMedCrossRef Sandborn WJ, Pardi DS. Clinical management of pouchitis. Gastroenterology 2004;127:1809–14.PubMedCrossRef
4.
Zurück zum Zitat Mahadevan U, Sandborn WJ. Diagnosis and treatment of pouchitis. Gastroenterology 2003;124:1636–50.PubMedCrossRef Mahadevan U, Sandborn WJ. Diagnosis and treatment of pouchitis. Gastroenterology 2003;124:1636–50.PubMedCrossRef
5.
Zurück zum Zitat Hurst RD, Molinari M, Chung TP, Rubin M, Michelassi F. Prospective study on the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg 1996;131:497–502.PubMedCrossRef Hurst RD, Molinari M, Chung TP, Rubin M, Michelassi F. Prospective study on the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg 1996;131:497–502.PubMedCrossRef
6.
Zurück zum Zitat Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Brzezinski A, Bevins CL, Bambrick ML, Seidner DL, Fazio VW. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001;7:301–5.PubMedCrossRef Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Brzezinski A, Bevins CL, Bambrick ML, Seidner DL, Fazio VW. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001;7:301–5.PubMedCrossRef
7.
Zurück zum Zitat Mimura T, Rizzello F, Hleweg U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ; Gionchetti P, Campieri M, Kamm A. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002;16:909–17.PubMedCrossRef Mimura T, Rizzello F, Hleweg U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ; Gionchetti P, Campieri M, Kamm A. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002;16:909–17.PubMedCrossRef
8.
Zurück zum Zitat Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriothreapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305–9.PubMedCrossRef Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriothreapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305–9.PubMedCrossRef
9.
Zurück zum Zitat Lim M, Sagar P, Finan P, Burke D, Schuster H. Dysbiosis and pouchitis. Br J Surg 2006;93:1325–34.PubMedCrossRef Lim M, Sagar P, Finan P, Burke D, Schuster H. Dysbiosis and pouchitis. Br J Surg 2006;93:1325–34.PubMedCrossRef
10.
Zurück zum Zitat Mann SD, Pitt J, Springall RG, Thillainayagam AV. Clostridium difficile infection—an unusual cause of refractory pouchitis: report of a case. Dis Colon Rectum. 2003 Feb;46(2):267–70.PubMedCrossRef Mann SD, Pitt J, Springall RG, Thillainayagam AV. Clostridium difficile infection—an unusual cause of refractory pouchitis: report of a case. Dis Colon Rectum. 2003 Feb;46(2):267–70.PubMedCrossRef
11.
Zurück zum Zitat Shen B, Goldblum JR, Hull TL, Remzi FH, Bennett AE, Fazio VW. Clostridium difficile-associated pouchitis. Dig Dis Sci. 2006 Dec;51(12):2361–4.PubMedCrossRef Shen B, Goldblum JR, Hull TL, Remzi FH, Bennett AE, Fazio VW. Clostridium difficile-associated pouchitis. Dig Dis Sci. 2006 Dec;51(12):2361–4.PubMedCrossRef
12.
Zurück zum Zitat Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG. Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis Colon Rectum 2004; 47: 1519–25PubMedCrossRef Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG. Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis Colon Rectum 2004; 47: 1519–25PubMedCrossRef
13.
Zurück zum Zitat Duffy M. O’Mahony L, Coffey JC, Collins JK, Shanahan F, Redmond HP, Kirwan WO. Sulfate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial adenomatous polyposis. Dis Colon Rectum 2002; 45: 384–8PubMedCrossRef Duffy M. O’Mahony L, Coffey JC, Collins JK, Shanahan F, Redmond HP, Kirwan WO. Sulfate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial adenomatous polyposis. Dis Colon Rectum 2002; 45: 384–8PubMedCrossRef
14.
Zurück zum Zitat Ohge H. Furne JK, Springfield J, Rothenberger DA, Madoff RD, Levitt MD. Association between fecal hydrogen sulfide production and pouchitis. Dis Colon Rectum 2005; 48:469–75PubMedCrossRef Ohge H. Furne JK, Springfield J, Rothenberger DA, Madoff RD, Levitt MD. Association between fecal hydrogen sulfide production and pouchitis. Dis Colon Rectum 2005; 48:469–75PubMedCrossRef
15.
Zurück zum Zitat Nicholls RJ, Banerjee AK. Pouchitis: risk factors, etiology, and treatment. World J Surg. 1998 Apr;22(4):347–51.PubMedCrossRef Nicholls RJ, Banerjee AK. Pouchitis: risk factors, etiology, and treatment. World J Surg. 1998 Apr;22(4):347–51.PubMedCrossRef
16.
Zurück zum Zitat Scarpa M, Grillo A, Pozza A, Faggian D, Ruffolo C, Scarpa M, D’Incà R, Plebani M, Sturniolo GC, Castagliuolo I, Angriman I. TLR2 and TLR4 up-regulation and colonization of the ileal mucosa by Clostridiaceae spp. in chronic/relapsing pouchitis. J Surg Res 2011 169:145–154CrossRef Scarpa M, Grillo A, Pozza A, Faggian D, Ruffolo C, Scarpa M, D’Incà R, Plebani M, Sturniolo GC, Castagliuolo I, Angriman I. TLR2 and TLR4 up-regulation and colonization of the ileal mucosa by Clostridiaceae spp. in chronic/relapsing pouchitis. J Surg Res 2011 169:145–154CrossRef
17.
Zurück zum Zitat Scarpa M, Grillo A, Faggian D, Ruffolo C, Bonello E, D’Incà R, Scarpa M, Castagliuolo I, Angriman I. Relationship between mucosa-associated microbiota and inflammatory parameters in the ileal pouch after restorative proctocolectomy for ulcerative colitis. Surgery 2011 150:56–67PubMedCrossRef Scarpa M, Grillo A, Faggian D, Ruffolo C, Bonello E, D’Incà R, Scarpa M, Castagliuolo I, Angriman I. Relationship between mucosa-associated microbiota and inflammatory parameters in the ileal pouch after restorative proctocolectomy for ulcerative colitis. Surgery 2011 150:56–67PubMedCrossRef
18.
Zurück zum Zitat Cario E. Bacterial interactions with cells of the intestinal mucosa: toll-like receptors and NOD2. Gut 2005;54:1182–93.PubMedCrossRef Cario E. Bacterial interactions with cells of the intestinal mucosa: toll-like receptors and NOD2. Gut 2005;54:1182–93.PubMedCrossRef
19.
Zurück zum Zitat Toiyama Y, Araki T, Yoshiyama S, Hiro J, Miki C, Kusunoki M. The expression patterns of Toll-like receptors in the ileal pouch mucosa of postoperative ulcerative colitis patients. Surg Today. 2006;36(3):287–90.PubMedCrossRef Toiyama Y, Araki T, Yoshiyama S, Hiro J, Miki C, Kusunoki M. The expression patterns of Toll-like receptors in the ileal pouch mucosa of postoperative ulcerative colitis patients. Surg Today. 2006;36(3):287–90.PubMedCrossRef
20.
Zurück zum Zitat Haller D, Russo MP, Sartor RB, Jobin C. IKK beta and phosphatidylinositol 3-kinase/Akt participate in non-pathogenic Gram-negative enteric bacteria-induced RelA phosphorylation and NF-kappa B activation in both primary and intestinal epithelial cell lines. J Biol Chem 2002;277:38168–78.PubMedCrossRef Haller D, Russo MP, Sartor RB, Jobin C. IKK beta and phosphatidylinositol 3-kinase/Akt participate in non-pathogenic Gram-negative enteric bacteria-induced RelA phosphorylation and NF-kappa B activation in both primary and intestinal epithelial cell lines. J Biol Chem 2002;277:38168–78.PubMedCrossRef
22.
Zurück zum Zitat Fellermann K, Stange EF. Defensins-innate immunity at the epithelial frontier. Eur J Gastroenterol Hepatol 2001;13:771–6.PubMedCrossRef Fellermann K, Stange EF. Defensins-innate immunity at the epithelial frontier. Eur J Gastroenterol Hepatol 2001;13:771–6.PubMedCrossRef
23.
Zurück zum Zitat Lehrer RI, Barton A, Daher KA, et al. Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity. J Clin Invest 1989;84:553–61.PubMedCrossRef Lehrer RI, Barton A, Daher KA, et al. Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity. J Clin Invest 1989;84:553–61.PubMedCrossRef
24.
Zurück zum Zitat Kagan BL, Selsted ME, Ganz T, et al. Antimicrobial defensin peptides form voltage-dependent ion-permeable channels in planar lipid bilayer membranes. Proc Natl Acad Sci U S A 1990;87:210–14.PubMedCrossRef Kagan BL, Selsted ME, Ganz T, et al. Antimicrobial defensin peptides form voltage-dependent ion-permeable channels in planar lipid bilayer membranes. Proc Natl Acad Sci U S A 1990;87:210–14.PubMedCrossRef
25.
Zurück zum Zitat Chertov O, Michiel DF, Xu L, et al. Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem 1996;271:2935–40.PubMedCrossRef Chertov O, Michiel DF, Xu L, et al. Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem 1996;271:2935–40.PubMedCrossRef
26.
Zurück zum Zitat Jones DE, Bevins CL. Paneth cells of the human small intestine express an antimicrobial peptide gene. J Biol Chem 1992;267:23216–25.PubMed Jones DE, Bevins CL. Paneth cells of the human small intestine express an antimicrobial peptide gene. J Biol Chem 1992;267:23216–25.PubMed
27.
Zurück zum Zitat Cunliffe RN, Rose FRAJ, Keyte J, et al. Human defensin 5 is stored in precursor form in normal Paneth cells and is expressed by some villous epithelial cells and by metaplastic Paneth cells in the colon in inflammatory bowel disease. Gut 2001;48:176–85.PubMedCrossRef Cunliffe RN, Rose FRAJ, Keyte J, et al. Human defensin 5 is stored in precursor form in normal Paneth cells and is expressed by some villous epithelial cells and by metaplastic Paneth cells in the colon in inflammatory bowel disease. Gut 2001;48:176–85.PubMedCrossRef
28.
Zurück zum Zitat Wehkamp J, Schwind B, Herrlinger KR, Baxmann S, Schmidt K, Duchrow M, Wohlschlager C, Feller AC, Stange EF, Fellermann K. Innate immunity and colonic inflammation: enhanced expression of epithelial alpha-defensins. Dig Dis Sci 2002; 47: 1349–1355PubMedCrossRef Wehkamp J, Schwind B, Herrlinger KR, Baxmann S, Schmidt K, Duchrow M, Wohlschlager C, Feller AC, Stange EF, Fellermann K. Innate immunity and colonic inflammation: enhanced expression of epithelial alpha-defensins. Dig Dis Sci 2002; 47: 1349–1355PubMedCrossRef
29.
Zurück zum Zitat Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn’s disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet 2001;10:445–56.PubMedCrossRef Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn’s disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet 2001;10:445–56.PubMedCrossRef
30.
Zurück zum Zitat O’Neil DA, Porter EM, Elewaut D, et al. Expression and regulation of the human b-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol 1999;163:6718–24.PubMed O’Neil DA, Porter EM, Elewaut D, et al. Expression and regulation of the human b-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol 1999;163:6718–24.PubMed
31.
Zurück zum Zitat Scarpa M, van Koperen PJ, Ubbink DT, Hommes DW, ten Kate FJW, Bemelman WA. Systematic review of dysplasia after restorative proctocolectomy for ulcerative colitis. Br J Surg 2007;94:534–45.PubMedCrossRef Scarpa M, van Koperen PJ, Ubbink DT, Hommes DW, ten Kate FJW, Bemelman WA. Systematic review of dysplasia after restorative proctocolectomy for ulcerative colitis. Br J Surg 2007;94:534–45.PubMedCrossRef
32.
Zurück zum Zitat Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch–anal anastomosis: pouchitis activity index. Mayo Clinic Proc 1994;69:409–15. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch–anal anastomosis: pouchitis activity index. Mayo Clinic Proc 1994;69:409–15.
33.
Zurück zum Zitat Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997;25:3389–402.PubMedCrossRef Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997;25:3389–402.PubMedCrossRef
34.
Zurück zum Zitat Ghosh D, Porter E, Shen B, Lee SK, Wilk D, Drazba J, Yadav SP, Crabb JW, Ganz T, Bevins CL. Paneth cell trypsin is the processing enzyme for human defensin-5. Nat Immunol. 2002 Jun;3(6):583–90.PubMedCrossRef Ghosh D, Porter E, Shen B, Lee SK, Wilk D, Drazba J, Yadav SP, Crabb JW, Ganz T, Bevins CL. Paneth cell trypsin is the processing enzyme for human defensin-5. Nat Immunol. 2002 Jun;3(6):583–90.PubMedCrossRef
35.
Zurück zum Zitat Nuding S, Fellermann K, Wehkamp J, Mueller HA, Stange EF. A flow cytometric assay to monitor antimicrobial activity of defensins and cationic tissue extracts. J Microbiol Methods. 2006 May;65(2):335–45.PubMedCrossRef Nuding S, Fellermann K, Wehkamp J, Mueller HA, Stange EF. A flow cytometric assay to monitor antimicrobial activity of defensins and cationic tissue extracts. J Microbiol Methods. 2006 May;65(2):335–45.PubMedCrossRef
36.
Zurück zum Zitat Ruffolo C, Scarpa M, Faggian D, Pozza A, Navaglia F, D’Inca R, Hoxha P, Romanato G, Polese L, Sturniolo GC, Plebani M, D’Amico DF, Angriman I. Cytokine network in rectal mucosa in perianal Crohn’s disease: relations with inflammatory parameters and need for surgery. Inflamm Bowel Dis 2008;14:1406–12.PubMedCrossRef Ruffolo C, Scarpa M, Faggian D, Pozza A, Navaglia F, D’Inca R, Hoxha P, Romanato G, Polese L, Sturniolo GC, Plebani M, D’Amico DF, Angriman I. Cytokine network in rectal mucosa in perianal Crohn’s disease: relations with inflammatory parameters and need for surgery. Inflamm Bowel Dis 2008;14:1406–12.PubMedCrossRef
37.
Zurück zum Zitat Scarpa M, D’Incà R, Basso D, Ruffolo C, Polese L, Bertin E, Luise A, Frego M, Plebani M, Sturniolo GC, D’Amico DF, Angriman I. Faecal lactoferrin and calprotectin after ileo-colonic resection for Crohn’s disease. Dis Colon Rectum 2007;50:861–9.PubMedCrossRef Scarpa M, D’Incà R, Basso D, Ruffolo C, Polese L, Bertin E, Luise A, Frego M, Plebani M, Sturniolo GC, D’Amico DF, Angriman I. Faecal lactoferrin and calprotectin after ileo-colonic resection for Crohn’s disease. Dis Colon Rectum 2007;50:861–9.PubMedCrossRef
38.
Zurück zum Zitat International Council for Standardization in Haematology (Expert Panel on Blood Rheology). ICSH recommendations for measurement of erythrocyte sedimentation rate. J Clin Pathol 1993;46:198–203. International Council for Standardization in Haematology (Expert Panel on Blood Rheology). ICSH recommendations for measurement of erythrocyte sedimentation rate. J Clin Pathol 1993;46:198–203.
39.
Zurück zum Zitat Dominici R, Luraschi P, Franzini C. Measurement of C-reactive protein: two high sensitivity methods compared. J Clin Lab Anal 2004;18:280–4.PubMedCrossRef Dominici R, Luraschi P, Franzini C. Measurement of C-reactive protein: two high sensitivity methods compared. J Clin Lab Anal 2004;18:280–4.PubMedCrossRef
40.
Zurück zum Zitat Brooks SP, Lampi BJ, Sarwar G, Botting HG. A comparison of methods for determining total body protein. Anal Biochem 1995;226:26–30.PubMedCrossRef Brooks SP, Lampi BJ, Sarwar G, Botting HG. A comparison of methods for determining total body protein. Anal Biochem 1995;226:26–30.PubMedCrossRef
41.
Zurück zum Zitat Henderson AR. Assessing test accuracy on its clinical consequence: a primer for receiver operative characteristics curve analysis. Ann Clin Biochem 1993; 30: 521–539.PubMed Henderson AR. Assessing test accuracy on its clinical consequence: a primer for receiver operative characteristics curve analysis. Ann Clin Biochem 1993; 30: 521–539.PubMed
42.
Zurück zum Zitat Kiehne K, Brunke G, Wegner F, Banasiewicz T, Fölsch UR, Herzig KH. Defensin expression in chronic pouchitis in patients with ulcerative colitis or familial adenomatous polyposis coli. World J Gastroenterol 2006; 21; 12(7):1056–1062 Kiehne K, Brunke G, Wegner F, Banasiewicz T, Fölsch UR, Herzig KH. Defensin expression in chronic pouchitis in patients with ulcerative colitis or familial adenomatous polyposis coli. World J Gastroenterol 2006; 21; 12(7):1056–1062
43.
Zurück zum Zitat Harder J, Meyer-Hoffert U, Teran LM, Schwichtenberg L, Bartels J, Maune S, Schroder JM. Mucoid Pseudomonas aeruginosa, TNF-alpha, and IL-1beta, but not IL-6, induce human beta-defensin-2 in respiratory epithelia. Am J Respir Cell Mol Biol 2000; 22: 714–721PubMed Harder J, Meyer-Hoffert U, Teran LM, Schwichtenberg L, Bartels J, Maune S, Schroder JM. Mucoid Pseudomonas aeruginosa, TNF-alpha, and IL-1beta, but not IL-6, induce human beta-defensin-2 in respiratory epithelia. Am J Respir Cell Mol Biol 2000; 22: 714–721PubMed
45.
Zurück zum Zitat Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, et al. Reduced Paneth cell a-defensins in ileal Crohn’s disease. Proc Nat Acad Sci USA 2005; 102: 18129–18134.PubMedCrossRef Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, et al. Reduced Paneth cell a-defensins in ileal Crohn’s disease. Proc Nat Acad Sci USA 2005; 102: 18129–18134.PubMedCrossRef
46.
Zurück zum Zitat Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaeffeler E, et al. NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal a-defensin expression. Gut 2004; 53: 1658–1664.PubMedCrossRef Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaeffeler E, et al. NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal a-defensin expression. Gut 2004; 53: 1658–1664.PubMedCrossRef
47.
Zurück zum Zitat Nuding S, Fellermann K, Wehkamp J, Stange EF. Reduced mucosal antimicrobial activity in Crohn’s disease of the colon. Gut 2007; 56: 1240–1247.PubMedCrossRef Nuding S, Fellermann K, Wehkamp J, Stange EF. Reduced mucosal antimicrobial activity in Crohn’s disease of the colon. Gut 2007; 56: 1240–1247.PubMedCrossRef
48.
Zurück zum Zitat Noble CL, Abbas AR, Cornelius J, Lees CW, Ho GT, et al. Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis. Gut 2008; 57: 1398–1405.PubMedCrossRef Noble CL, Abbas AR, Cornelius J, Lees CW, Ho GT, et al. Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis. Gut 2008; 57: 1398–1405.PubMedCrossRef
49.
Zurück zum Zitat Shepherd NA, Healey CJ, Warren BF, Richman PI, Thomson WH, Wilkinson SP. Distribution of mucosal pathology and an assessment of colonic phenotypic change in the pelvic ileal reservoir. Gut 1993; 34: 101–105PubMedCrossRef Shepherd NA, Healey CJ, Warren BF, Richman PI, Thomson WH, Wilkinson SP. Distribution of mucosal pathology and an assessment of colonic phenotypic change in the pelvic ileal reservoir. Gut 1993; 34: 101–105PubMedCrossRef
50.
Zurück zum Zitat Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Folsch UR, Timmis KN, Schreiber S. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004; 53: 685–693PubMedCrossRef Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Folsch UR, Timmis KN, Schreiber S. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004; 53: 685–693PubMedCrossRef
51.
Zurück zum Zitat Wehkamp J, Wang G, Kubler I, Nuding S, Gregorieff A, Schnabel A, Kays RJ, Fellermann K, Burk O, Schwab M, Clevers H, Bevins CL, Stange EF. The Paneth cell α-defensin deficiency of ileal Crohn’s disease is linked to Wnt/Tcf-4. J Immunol, 2007, 179: 3109–3118.PubMed Wehkamp J, Wang G, Kubler I, Nuding S, Gregorieff A, Schnabel A, Kays RJ, Fellermann K, Burk O, Schwab M, Clevers H, Bevins CL, Stange EF. The Paneth cell α-defensin deficiency of ileal Crohn’s disease is linked to Wnt/Tcf-4. J Immunol, 2007, 179: 3109–3118.PubMed
Metadaten
Titel
Innate Immune Environment in Ileal Pouch Mucosa: α5 Defensin Up-regulation as Predictor of Chronic/Relapsing Pouchitis
verfasst von
Marco Scarpa
Alessia Grillo
Melania Scarpa
Paola Brun
Carlo Castoro
Anna Pozza
Donatella Cavallo
Diego Faggian
Cesare Ruffolo
Renata D’Incà
Romeo Bardini
Ignazio Castagliuolo
Imerio Angriman
Publikationsdatum
01.01.2012
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 1/2012
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-011-1720-6

Weitere Artikel der Ausgabe 1/2012

Journal of Gastrointestinal Surgery 1/2012 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.